Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, Bertz S, Neuzillet Y, Sanders J, Otto W, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Trombetta C, Eckstein M, Mertens LS, Burger M, Soorojebally Y, Wullich B, Bartoletti R, Radvanyi F, Pavan N, Sirab N, Mir MC, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Bussani R, Allory Y, van Rhijn BWG. Claps F, et al. Among authors: sanders j. BJU Int. 2023 Aug;132(2):170-180. doi: 10.1111/bju.15984. Epub 2023 Feb 20. BJU Int. 2023. PMID: 36748180 Free article.
Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept.
Neuzillet Y, Mertens L, Shariat S, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B. Neuzillet Y, et al. Among authors: sanders j. Prog Urol. 2014 Nov;24(13):806-7. doi: 10.1016/j.purol.2014.08.054. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461579 French. No abstract available.
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW. Pouessel D, et al. Among authors: sanders j. Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18. Ann Oncol. 2016. PMID: 27091807 Free PMC article.
Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.
Fransen van de Putte EE, Pos F, Doodeman B, van Rhijn BWG, van der Laan E, Nederlof P, van der Heijden MS, Bloos-van der Hulst J, Sanders J, Broeks A, Kerst JM, van der Noort V, Horenblas S, Bergman AM. Fransen van de Putte EE, et al. Among authors: sanders j. J Urol. 2019 Mar;201(3):478-485. doi: 10.1016/j.juro.2018.10.007. J Urol. 2019. PMID: 30321552
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.
van Rhijn BWG, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, van der Heijden MS, Jewett MAS, Marquez M, Stoehr R, Zlotta AR, Eckstein M, Soorojebally Y, Roshani H, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, Wullich B, van der Kwast TH, Malats N, Hartmann A, Allory Y, Zuiverloon TCM. van Rhijn BWG, et al. Among authors: sanders j. Eur Urol. 2020 Nov;78(5):682-687. doi: 10.1016/j.eururo.2020.07.002. Epub 2020 Jul 15. Eur Urol. 2020. PMID: 32682615
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
Mertens LS, Claps F, Mayr R, Bostrom PJ, Shariat SF, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, Peters D, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Eckstein M, Soorojebally Y, van der Schoot DKE, Wullich B, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Allory Y, Zuiverloon TCM, van Rhijn BWG. Mertens LS, et al. Among authors: sanders j. Urol Oncol. 2022 Mar;40(3):110.e1-110.e9. doi: 10.1016/j.urolonc.2021.10.010. Epub 2021 Dec 11. Urol Oncol. 2022. PMID: 34906411 Free article.
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
van Dijk N, Gil-Jimenez A, Silina K, van Montfoort ML, Einerhand S, Jonkman L, Voskuilen CS, Peters D, Sanders J, Lubeck Y, Broeks A, Hooijberg E, Vis DJ, van den Broek M, Wessels LFA, van Rhijn BWG, van der Heijden MS. van Dijk N, et al. Among authors: sanders j. Front Immunol. 2021 Dec 20;12:793964. doi: 10.3389/fimmu.2021.793964. eCollection 2021. Front Immunol. 2021. PMID: 34987518 Free PMC article. Clinical Trial.
The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis.
Mertens LS, Claps F, Mayr R, Hodgson A, Shariat SF, Hippe K, Neuzillet Y, Sanders J, Burger M, Pouessel D, Otto W, van der Kwast TH, Lotan Y, Allory Y, Downes MR, van Rhijn BWG. Mertens LS, et al. Among authors: sanders j. Int J Surg Pathol. 2023 Apr;31(2):157-166. doi: 10.1177/10668969221095173. Epub 2022 Apr 24. Int J Surg Pathol. 2023. PMID: 35466737 Free article.
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
Versluis JM, Blankenstein SA, Dimitriadis P, Wilmott JS, Elens R, Blokx WAM, van Houdt W, Menzies AM, Schrage YM, Wouters MWJM, Sanders J, Broeks A, Scolyer RA, Suijkerbuijk KPM, Long GV, Akkooi ACJV, Blank CU. Versluis JM, et al. Among authors: sanders j. J Immunother Cancer. 2024 Apr 27;12(4):e008125. doi: 10.1136/jitc-2023-008125. J Immunother Cancer. 2024. PMID: 38677880 Free PMC article.
3,324 results